{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:40:21Z","timestamp":1773114021319,"version":"3.50.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>A significant number of patients receiving therapy with antitumor necrosis factor (TNF) agents for Crohn\u2019s disease experience primary or secondary nonresponse. The aim of this study was to assess whether patients with nonresponse to anti-TNF agents have increased expression of alternative cytokine pathways.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We designed a prospective, cross-sectional study that included patients with Crohn\u2019s disease receiving anti-TNF undergoing colonoscopy with adequate serum trough drug levels (\u22658\u2009\u00b5g\/mL) and without anti-drug antibodies. Inflammatory cytokines and cell adhesions markers measured included intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1, interleukin (IL)-8, IL-1\u03b2, and IL-6. The primary outcome was the presence of active endoscopic inflammation defined as the presence of at least 1 ulceration \u22655\u2009mm.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In total, 47 patients were included. Patients with active inflammation had significantly higher levels of ICAM-1 and IL-1\u03b2 when compared with those without intestinal inflammation (45.9 vs. 35.8\u2009ng\/mL, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001 and 3.2 vs. 1.5\u2009pg\/mL, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.002, respectively). There were no significant differences in the other study variables. Using receiving operating curves, ICAM and IL-1\u03b2 had a good correlation (receiver operating characteristic \u22650.8) with inflammation in this cohort of patients with \u201canti-TNF resistance.\u201d The results were similar in the group of patients with previous anti-TNF exposure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Our study suggests that patients who have active inflammation with seemingly adequate serum anti-TNF levels have increased levels of specific inflammatory pathways that may serve as biomarkers of nonresponse as well as potential targets of therapy in anti-TNF nonresponders.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcg.0000000000001002","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T20:51:14Z","timestamp":1520369474000},"page":"210-215","source":"Crossref","is-referenced-by-count":10,"title":["Inflammatory Cytokine Profile in Crohn\u2019s Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy"],"prefix":"10.1097","volume":"53","author":[{"given":"Andres J.","family":"Yarur","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Jain","sequence":"additional","affiliation":[{"name":"Prometheus Laboratories, San Diego, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Quintero","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Czul","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar R.","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Kerman","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria T.","family":"Abreu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230913","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"R2-20230913","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"R3-20230913","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R4-20230913","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/MIB.0000000000000380","article-title":"Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases","volume":"21","author":"Yarur","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R5-20230913","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R6-20230913","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-20230913","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the Classic-I Trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"R8-20230913","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"R9-20230913","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MIB.0000000000000689","article-title":"Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn\u2019s disease and ulcerative colitis","volume":"22","author":"Yarur","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R10-20230913","doi-asserted-by":"crossref","first-page":"1118.e3","DOI":"10.1016\/j.cgh.2014.12.026","article-title":"Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy","volume":"13","author":"Yarur","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"suppl A","key":"R11-20230913","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"R12-20230913","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/gut.36.5.724","article-title":"Adhesion molecules in inflammatory bowel disease","volume":"36","author":"Jones","year":"1995","journal-title":"Gut"},{"key":"R13-20230913","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"R14-20230913","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1432-1033.1997.00215.x","article-title":"Leukocyte adhesion\u2014structure and function of human leukocyte beta2-integrins and their cellular ligands","volume":"245","author":"Gahmberg","year":"1997","journal-title":"Eur J Biochem"},{"key":"R15-20230913","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/gutjnl-2013-306518","article-title":"Identification of inflammatory mediators in patients with Crohn\u2019s disease unresponsive to anti-TNF therapy","volume":"64","author":"Leal","year":"2015","journal-title":"Gut"},{"key":"R16-20230913","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat Med"},{"key":"R17-20230913","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn\u2019s disease","volume":"126","author":"Ito","year":"2004","journal-title":"Gastroenterology"},{"key":"R18-20230913","first-page":"3157","article-title":"Interleukin-8 and SDF1-alpha mRNA expression in colonic biopsies from patients with inflammatory bowel disease","volume":"95","author":"Katsuta","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R19-20230913","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/gut.38.2.216","article-title":"Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease","volume":"38","author":"Daig","year":"1996","journal-title":"Gut"},{"key":"R20-20230913","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1111\/j.1572-0241.1999.01288.x","article-title":"Clinical relevance of serum interleukin-6 in Crohn\u2019s disease: single point measurements, therapy monitoring, and prediction of clinical relapse","volume":"94","author":"Reinisch","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R21-20230913","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1053\/gast.2001.29568","article-title":"Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1\/Yit adoptive transfer model of Crohn\u2019s disease in mice","volume":"121","author":"Burns","year":"2001","journal-title":"Gastroenterology"},{"key":"R22-20230913","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cgh.2006.11.001","article-title":"A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn\u2019s disease","volume":"5","author":"Yacyshyn","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R23-20230913","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1136\/gut.2003.036160","article-title":"A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis","volume":"53","author":"van Deventer","year":"2004","journal-title":"Gut"},{"key":"R24-20230913","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/gutjnl-2014-308099","article-title":"The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study","volume":"65","author":"Yarur","year":"2016","journal-title":"Gut"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004836-201903000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:44:42Z","timestamp":1694641482000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201903000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000001002","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}